Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences Protein Patent Count Surpasses 4,000 as Firm Snatches Proteomics Lead

NEW YORK, Dec. 6 - Oxford GlycoSciences said it had achieved its goal of patenting more than 4,000 proteins and related genes, an achievement that will thrust the biotech company into the forefront of proteomics research.

 

"We believe that this is the largest single disease-associated protein patent portfolio," Michael Kranda, OGS's CEO, said in a statement released early Friday from the company's headquarters in the UK. "We see it [the patents] as a major corporate asset which constitutes the foundation on which we are building multiple internal drug discovery programmes."

 

OGS's proteomic patent portfolio includes potential targets for diseases that include cancers of the breast, liver, and pancreas, and CNS disorders like schizophrenia and dementia.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.